Journal
RADIOTHERAPY AND ONCOLOGY
Volume 150, Issue -, Pages 26-29Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2020.05.004
Keywords
SCLC; Limited disease small cell lung cancer; Decision making; BID radiotherapy; QD radiotherapy
Funding
- NIHR Manchester Biomedical Research Centre
Ask authors/readers for more resources
Background: In limited disease small cell lung cancer (LD-SCLC), the CONVERT trial has not demonstrated superiority of once-daily (QD) radiotherapy (66 Gy) over twice-daily (BID) radiotherapy (45 Gy). We explored the factors influencing the selection between QD and BID regimens. Methods: Thirteen experienced European thoracic radiation oncologists as selected by the European Society for Therapeutic Radiation Oncology (ESTRO) were asked to describe their strategies in the management of LD-SCLC. Treatment strategies were subsequently converted into decision trees and analysed for agreement and discrepancies. Results: Logistic reasons, patients' performance status and radiotherapy dose constraints were the three major decision criteria used by most experts in decision making. The use of QD and BID regimens was balanced among European experts, but there was a trend towards the BID regimen for fit patients able to travel twice a day to the radiotherapy site. Conclusion: BID and QD radiotherapy are both accepted regimens among experts and the decision is influenced by pragmatic factors such as availability of transportation. (C) 2020 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 150 (2020) 26-29
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available